Clinical Trial Update: Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating glutamic acid to reduce vincristine-induced nerve damage in young cancer patients; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer
• Leukemia
• Lymphoma
• Neurotoxicity
• Peripheral Neuropathy
• Sarcoma

Drugs mentioned

• Vincristine (vincristine)
• glutamic acid (glutamic acid)

Snippet

Sponsor: University of South Florida | Conditions: Kidney Cancer, Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2014-03-14